Circulant VEGF-A as a predictor of benefit for bevacizumab therapy for breast cancer patients: systematic review and meta-analysis

Name: Circulant VEGF-A as a predictor of benefit for bevacizumab therapy for breast cancer patients: systematic review and meta-analysis
Creator: Centre for Reviews and Dissemination - CRD
Published: 2015-08-07T11:10:53+08:00